MANUFACTURING AND SUPPLY AGREEMENT BY AND BETWEEN SUCAMPO AG AND PAR PHARMACEUTICAL, INC. DATED AS OF SEPTEMBER 30, 2014Manufacturing and Supply Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Manufacturing and Supply Agreement (this “Agreement”) is hereby entered into and effective as of September [ ], 2014 (the “Effective Date”) by and between Sucampo AG (“Sucampo”) and Par Pharmaceutical, Inc. (“Par”). Each of Sucampo and Par are referred hereto as the “Parties” or, individually, as a “Party”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is made and effective as of September ___, 2014 (the “Effective Date”), by and between, on the one hand, Sucampo AG and Sucampo Pharmaceuticals, Inc. (collectively, “Sucampo”), R-Tech Ueno, Ltd. (“RTU”), Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals USA, Inc. and Takeda Pharmaceuticals America, Inc. (collectively, “Takeda”), and on the other hand, Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc. (collectively, “Par”). Sucampo, RTU, Takeda, and Par are collectively referred to as the “Parties,” and each separately as a “Party.”
AMENDMENT NO. 1 TO AGREEMENTTo Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 is made and entered into as of September 30, 2014 (the “Effective Date”), by and between Sucampo Pharma Americas, LLC (formerly known as Sucampo Pharma Americas, Inc., which was further formerly known as Sucampo Pharmaceuticals, Inc.) (“SPA”), Takeda Pharmaceutical Company Limited (“Takeda”) and Sucampo AG (“SAG”). SPA, Takeda and SAG are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO SUPPLY AGREEMENT AND SUPPLY AND PURCHASE AGREEMENT AND ADDENDUM TO SUPPLY & PURCHASE AGREEMENTSupply Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 is made and entered into as of September 30, 2014 (the “Effective Date”), by and between Sucampo Pharma Americas, LLC (formerly known as Sucampo Pharma Americas, Inc., which was further formerly known as Sucampo Pharmaceuticals, Inc.) (“SPA”), Takeda Pharmaceutical Company Limited (“Takeda”) and R-Tech Ueno, Ltd. (“RTU”). SPA, Takeda and RTU are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT AND SUPPLEMENTAL AGREEMENTCollaboration and License Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 is made and entered into as of September 30, 2014 (the “Effective Date”), by and between Sucampo Pharma Americas, LLC (formerly known as Sucampo Pharma Americas, Inc., which was further formerly known as Sucampo Pharmaceuticals, Inc.) (“Sucampo”) and Takeda Pharmaceutical Company Limited (“Takeda”). Sucampo and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTLubiprostone Exclusive Manufacturing and Supply Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT ("Agreement") is made this 1st day of January 2014 (the "Effective Date"), by and between Sucampo AG, a corporation organized and existing under the laws of Switzerland, and having its principal office at Baarerstrasse 22, 6300 Zug, Switzerland ("SAG"), and R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, Japan ("RTU") (each referred to herein as a "Party" and collectively as the "Parties").
